news
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang

 

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

The total transaction amount is approximately $2 billion, marking the largest take-private deal announced so far this year.

Haiwen & Partners served as legal counsel to one of the consortium members of the offeror, China State-Owned Enterprise Mixed Ownership Reform Fund, providing legal services in both Mainland China and Hong Kong. Meanwhile, Clifford Chance acted as the legal advisor to CITIC Securities, the financial advisor to the offeror.

The consortium behind the offeror comprises the Mixed Ownership Fund, Sinopharm (Hong Kong), Advanced Manufacturing Industry Investment Fund Phase II, China Reform Development Investment Management, Chongqing Fuling Industry Development Group, and Red Investment Limited.

China TCM primarily engages in the production and sale of traditional Chinese medicine and pharmaceutical products, focusing on Chinese medicine granules, patent medicines, and Chinese medicinal slices. China TCM has been listed in Hong Kong since 1993.

The Haiwen team was led by partners Wu Zuolong and Lin Xixiang, while partner Tommy Tam led the Clifford Chance team.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

INDIA REPORT: Merger Momentum

by Nimitt Dixit |

Despite global uncertainties, India's M&A landscape remains robust, with domestic deals driving growth and diverse sectors attracting investments. Experts predict a positive outlook for H2 2024, bolstered by policy continuity and abundant dry powder.

Simpson Thacher, Nishimura act on Blackstone’s $2.17 bln Japan pharma sale

by Nimitt Dixit |

Japanese law firm Nishimura & Asahi has represented private equity group MBK Partners on its acquisition of drugmaker Alinamin Pharmaceuticals for 350 billion yen ($2.17 billion) from PE giant Blackstone, which was advised by its longstanding firm Simpson Thacher & Bartlett.

Top CAM dealmaker rocks market with move to Khaitan

by Nimitt Dixit |

Top Indian dealmaker Shishir Vayttaden has left the equity partnership at Cyril Amarchand Mangaldas to join Khaitan & Co, along with two other partners in his team, K. Aishwarya and Aditi Singhvi.